Indeed, EZH2 acts mainly as a gene silencer in the progression of cancers such as breast [20] and prostate cancer [19], [21], and the overexpression of EZH2 is associated with aggressive and metastatic disease. This evidence concerns the gene EZH2 and metastatic neoplasm.